TP53 and Miyoshi myopathy: Furthermore, the level of TP53 amplification (≥51.25%) also showed a trend of positive correlation with patient survival rate. These data indicate that TP53, as a tumor suppressor, plays an important role in MM patient prognosis; patients with TP53 deletion at an earlier stage and patients of older ages will potentially have a decreased chance of reaching complete response when treated with standard chemotherapy and autologous hematopoietic cell transplantation therapy.